Table 3.

Association Between CCA IMT Progression and CMB Presence, Stratified by Hypertension Treatment

Exposure	Outcome	Model	No Hypertension Treatment (n=963)			Hypertension Treatment (n=261)			P Value for Interaction
			Participants With CMBs	OR (95% CI)	P Value	Participants With CMBs	OR (95% CI)	P Value
Change in CCA IMT (per SD increment)	Any CMB	1	63	0.78 (0.53–1.15)	0.22	36	0.89 (0.62–1.29)	0.55	0.68
		2	63	0.78 (0.53–1.14)	0.20	36	0.84 (0.57–1.23)	0.36	0.69
		3	63	0.78 (0.53–1.16)	0.22	36	0.83 (0.57–1.22)	0.35	0.68
	Lobar only	1	42	0.93 (0.62–1.39)	0.72	23	1.04 (0.81–1.32)	0.78	0.68
		2	42	0.95 (0.63–1.43)	0.81	23	0.98 (0.75–1.28)	0.90	0.60
		3	42	0.97 (0.64–1.48)	0.90	23	1.00 (0.76–1.30)	0.97	0.60
	Deep plus mixed	1	21	0.54 (0.27–1.09)	0.08	13	0.38 (0.17–0.87)	0.02	0.53
		2	21	0.51 (0.25–1.05)	0.07	13	0.41 (0.18–0.94)	0.03	0.57
		3	21	0.51 (0.24–1.05)	0.07	13	0.41 (0.18–0.96)	0.04	0.57

Model 1 was adjusted for age, sex, and years between exam 8 and MRI. Model 2 was additionally adjusted for diabetes, smoking, hypertension, systolic blood pressure, prevalent cardiovascular disease, and statin use. Model 3 was additionally adjusted for baseline carotid IMT. CCA indicates common carotid artery; CMB, cerebral microbleed; IMT, intima media thickness; OR, odds ratio.

A 1‐SD increment is 0.010 for CCA IMT.